Indian Immunologicals to invest Rs.700 Crores in Hyderabad for new animal vaccine facility
Doubling capacity of Foot and Mouth Disease vaccine for cattle to meet vaccine security of the nation.
HYDERABAD: In order to meet the nation's vaccine security needs against economically significant diseases like Foot and Mouth disease (FMD) and other emerging diseases, Indian Immunologicals Limited (IIL) announced on Monday that the company will invest approximately INR 700 Crores to establish a new animal vaccine manufacturing facility in Genome Valley, Hyderabad - the "Vaccine Hub of the World".
The facility is intended to be a state-of-art fully integrated biosafety level 3 (BSL-3) for Drug substance (DS) production and respective fill-finish. The facility is intended to be a state-of-art fully integrated biosafety level 3 (BSL-3) for Drug substance (DS) production and respective fill-finish.
IIL's planned new facility in Genome Valley Phase 3 will increase its FMD vaccine capacity by 300 million doses per year. The existing Gachibowli facility has a capacity of 300 million doses. Production is set to begin in the third year. IIL is a One Health company that is India's market leader in veterinary and human biologicals. It produces over 150 different products.
Dr. K. Anand Kumar, MD, IIL, and other members of the Executive Leadership team of IIL including Senior Vice Presidents Mr. Mukul Gaur and Mr. NSN Bhargav met with the Hon'ble Minister Mr. KT Rama Rao today and briefed the Minister on the company's plans. Mr. Jayesh Ranjan, Principal Secretary, Industries & Commerce and Mr. Shakthi M Nagappan, Director (Pharma & Lifesciences), Government of Telangana were also present during the meeting.
Minister K.T Rama Rao said, "I'm delighted that Indian Immunologicals will be setting up another greenfield facility in Genome Valley. Hyderabad is already regarded as the "Vaccine Capital of the World" and this expansion further advances our contribution in terms of global health, not just for humans but also for animals".
Dr. K. Anand Kumar, Managing Director, IIL mentioned, "IIL is on an aggressive growth path and this third vaccine facility in Hyderabad will ensure self-sufficiency for our nation in the field of vaccines and thereby saving the exchequer and farmers several thousands of crores".
IIL, a subsidiary National Dairy Development Board (NDDB) is already one of the largest manufacturers of FMD vaccine in the world and is the leading supplier of FMD vaccine to the Government of India's National Animal Disease Control Programme (NADCP). IIL is investing in a new greenfield project for the establishment of a Veterinary Vaccine Facility for manufacturing of Foot and Mouth Disease (FMD) vaccine and other animal vaccines.
All of these activities will be located in Genome Valley, India's first organised cluster for Life Sciences R&D and Clean Manufacturing activities, which will be equipped with world-class infrastructure facilities such as Industrial / Knowledge Parks, Special Economic Zones (SEZs), Multi-tenanted dry and wet laboratories, and incubation facilities. It is home to over 200 companies, with a scientific workforce of approximately 15,000 professionals, including the presence of marquee global names such as Novartis, GlaxoSmithKline, Ferring Pharma, Chemo, DuPont, Ashland, United States Pharmacopeia, Lonza, and many others, as well as vaccine manufacturers such as Bharat Biotech, Biological E, and others.